Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San Antonio Breast Cancer Symposium...
December 09 2016 - 7:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage
biotechnology company focused on the development of novel cancer
therapeutics, today announced that the company will host a live
conference call and webcast on Monday, December 12, 2016 at 8:30
a.m. EST (5:30 a.m. PST) to discuss recent CB-839 clinical data
presentations at the San Antonio Breast Cancer Symposium, the
EORTC-NCI-AACR Symposium, and other recent corporate highlights and
business developments.
The live audio webcast can be accessed via the Investor section
of the Company’s website at www.calithera.com. The conference call
can be accessed by dialing (855) 783-2599 (domestic) or (631)
485-4877 (international) and refer to conference ID 36690670.
Please log in approximately 5-10 minutes before the event to ensure
a timely connection. The archived webcast will remain
available for replay on Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally
bioavailable inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being evaluated
in Phase 1/2 clinical trials in combination with standard of care
agents. CB-1158 is a first-in-class immuno-oncology metabolic
checkpoint inhibitor targeting arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells. Arginase depletes arginine,
a nutrient that is critical for the activation, growth and survival
of the body’s cancer-fighting immune cells, known as cytotoxic
T-cells. CB-1158 is currently in a Phase I clinical
trial. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the
safety, tolerability and efficacy of CB-839, and the company’s
plans to continue development of CB-839. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. The potential product candidates
that Calithera develops may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all. In addition, clinical trials may not
confirm any safety, potency or other product characteristics
described or assumed in this press release. Such product
candidates may not be beneficial to patients or successfully
commercialized. The failure to meet expectations with respect
to any of the foregoing matters may have a negative effect on
Calithera's stock price. Additional information concerning
these and other risk factors affecting Calithera's business can be
found in Calithera's most recent Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission, and other
periodic filings with the Securities and Exchange Commission at
www.sec.gov. These forward-looking statements are not guarantees of
future performance and speak only as of the date hereof, and,
except as required by law, Calithera disclaims any obligation to
update these forward-looking statements to reflect future events or
circumstances.
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024